IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

COVID-19 Antiviral and Treatment Candidates: Current Status

  • Erica Espano (Department of Pharmacy, Korea University College of Pharmacy) ;
  • Dajung Kim (Department of Pharmacy, Korea University College of Pharmacy) ;
  • Jiyeon Kim (Department of Pharmacy, Korea University College of Pharmacy) ;
  • Song-Kyu Park (Department of Pharmacy, Korea University College of Pharmacy) ;
  • Jeong-Ki Kim (Department of Pharmacy, Korea University College of Pharmacy)
  • Received : 2021.01.10
  • Accepted : 2021.01.31
  • Published : 2021.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 has severely impacted global health and economy. There is currently no effective approved treatment for COVID-19; although vaccines have been granted emergency use authorization in several countries, they are currently only administered to high-risk individuals, thereby leaving a gap in virus control measures. The scientific and clinical communities and drug manufacturers have collaborated to speed up the discovery of potential therapies for COVID-19 by taking advantage of currently approved drugs as well as investigatory agents in clinical trials. In this review, we stratified some of these candidates based on their potential targets in the progression of COVID-19 and discuss some of the results of ongoing clinical evaluations.

Keywords

Acknowledgement

This work was supported by Korea University Research Grants (K1826621, K2005541 and K2023291). We thank Younsik Kim for the illustration.

References

  1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-574. https://doi.org/10.1016/S0140-6736(20)30251-8
  2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-273. https://doi.org/10.1038/s41586-020-2012-7
  3. The Johns Hopkins Coronavirus Resource Center (CRC). COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) 2020 [Internet]. Available at https://coronavirus.jhu.edu/map.html [accessed on 30 December 2020]. 
  4. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172:577-582. https://doi.org/10.7326/M20-0504
  5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-1720. https://doi.org/10.1056/NEJMoa2002032
  6. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26:672-675. https://doi.org/10.1038/s41591-020-0869-5
  7. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann Transl Med 2020;8:693.
  8. Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020;507:167-173. https://doi.org/10.1016/j.cca.2020.04.027
  9. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020;11:1446.
  10. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020;324:782-793. https://doi.org/10.1001/jama.2020.12839
  11. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res 2020;194:101-115. https://doi.org/10.1016/j.thromres.2020.06.029
  12. Carfi A, Bernabei R, Landi FGemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603-605. https://doi.org/10.1001/jama.2020.12603
  13. Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, Acosta S, Naqvi R, Burmeister-Morton F, Burmeister F, et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine 2020;26:100527.
  14. Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f ][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 2017;60:1648-1661. https://doi.org/10.1021/acs.jmedchem.6b01594
  15. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Gotte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020;295:6785-6797. https://doi.org/10.1074/jbc.RA120.013679
  16. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381:2293-2303. https://doi.org/10.1056/NEJMoa1910993
  17. Malin JJ, Suarez I, Priesner V, Fatkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 2020;34:e00162-e00120.
  18. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-271. https://doi.org/10.1038/s41422-020-0282-0
  19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9
  20. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020;382:2327-2336. https://doi.org/10.1056/NEJMoa2007016
  21. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020;383:1813-1826. https://doi.org/10.1056/NEJMoa2007764
  22. WHO Solidarity Trial ConsortiumPan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernandez Garcia C, Kieny MP, et al. Repurposed antiviral drugs for COVID-19 - interim WHO Solidarity trial results. N Engl J Med 2020. doi: 10.1056/NEJMoa2023184.
  23. Corbett AH, Lim ML, Kashuba ADM. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002;36:1193-1203. https://doi.org/10.1345/aph.1A363
  24. Kumar Y, Singh H, Patel CN. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health 2020;13:1210-1223. https://doi.org/10.1016/j.jiph.2020.06.016
  25. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RYT, Poon LLM, Wong CLP, Guan Y, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-256. https://doi.org/10.1136/thorax.2003.012658
  26. Park SY, Lee JS, Son JS, Ko JH, Peck KR, Jung Y, Woo HJ, Joo YS, Eom JS, Shi H. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect 2019;101:42-46. https://doi.org/10.1016/j.jhin.2018.09.005
  27. Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 2020;30:127377.
  28. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14:64-68. https://doi.org/10.5582/bst.2020.01030
  29. Kim JY, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee B, Park SJ. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020;35:e88.
  30. Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, Mo X, Wang J, Wang Y, Peng P, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med (N Y) 2020;1:105-113.e4. https://doi.org/10.1016/j.medj.2020.04.001
  31. Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, Palfreeman A, Raw J, Elmahi E, Prudon B, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020;396:1345-1352. https://doi.org/10.1016/S0140-6736(20)32013-4
  32. World Health Organization. "Solidarity" clinical trial for COVID-19 treatments [Internet]. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments [accessed on 10 September 2020]. 
  33. Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005;79:1943-1947. https://doi.org/10.1128/JVI.79.3.1943-1947.2005
  34. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001;98:6895-6900. https://doi.org/10.1073/pnas.111085598
  35. Rigopoulou EI, Abbott WGH, Williams R, Naoumov NV. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res 2007;75:36-42. https://doi.org/10.1016/j.antiviral.2006.11.008
  36. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3:e343.
  37. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005;326:905-908. https://doi.org/10.1016/j.bbrc.2004.11.128
  38. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013;19:1313-1317. https://doi.org/10.1038/nm.3362
  39. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014;14:1090-1095. https://doi.org/10.1016/S1473-3099(14)70920-X
  40. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, Jose J, Alraddadi B, Almotairi A, Al Khatib K, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis 2020;70:1837-1844. https://doi.org/10.1093/cid/ciz544
  41. Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, Jiang J. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents 2020;56:106114.
  42. Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, Ng YY, Lo J, Chan J, Tam AR, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:1695-1704. https://doi.org/10.1016/S0140-6736(20)31042-4
  43. Huang YQ, Tang SQ, Xu XL, Zeng YM, He XQ, Li Y, Harypursat V, Lu YQ, Wan Y, Zhang L, et al. No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, open-abeled prospective study. Front Pharmacol 2020;11:1071.
  44. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 2013;110:3991-3996. https://doi.org/10.1073/pnas.1203110110
  45. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 2014;7:131-140. https://doi.org/10.1177/1756283X13515825
  46. Ferreira AC, Reis PA, de Freitas CS, Sacramento CQ, Villas Boas Hoelz L, Bastos MM, Mattos M, Rocha N, Gomes de Azevedo Quintanilha I, da Silva Gouveia Pedrosa C, et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob Agents Chemother 2019;63:e01389-e18.
  47. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477.
  48. Jacome R, Campillo-Balderas JA, Ponce de Leon S, Becerra A, Lazcano A. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci Rep 2020;10:9294.
  49. Jockusch S, Tao C, Li X, Chien M, Kumar S, Morozova I, Kalachikov S, Russo JJ, Ju J. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep 2020;10:16577.
  50. Bahadur Gurung A, Ajmal Ali M, Lee J, Abul Farah M, Mashay Al-Anazi K. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. J King Saud Univ Sci 2020;32:2845-2853. https://doi.org/10.1016/j.jksus.2020.07.007
  51. Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, da Silva Gomes Dias S, Ferreira AC, Mattos M, Pao CR, de Freitas CS, Soares VC, Bozza FA, et al. The in vitro antiviral activity of the antihepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2. bioRxiv 2020. doi: 10.1101/2020.06.15.153411.
  52. Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, Hosamirudsai H, Afhami S, Akbarpour E, Aliannejad R, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother 2020;75:3379-3385. https://doi.org/10.1093/jac/dkaa334
  53. Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, Wentzel H, Hill A, Sadeghi A, Freeman J, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother 2020;75:3366-3372. https://doi.org/10.1093/jac/dkaa331
  54. Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, Levi J, Hill A, Shamshirian A. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 2020. doi: 10.1093/jac/dkaa501.
  55. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005;49:981-986. https://doi.org/10.1128/AAC.49.3.981-986.2005
  56. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 2011;55:782-787. https://doi.org/10.1128/AAC.01219-10
  57. Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 2014;69:2770-2784. https://doi.org/10.1093/jac/dku209
  58. Borrego B, de Avila AI, Domingo E, Brun A. Lethal mutagenesis of rift valley fever virus induced by favipiravir. Antimicrob Agents Chemother 2019;63:e00669-e19.
  59. de Avila AI, Gallego I, Soria ME, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS One 2016;11:e0164691. 
  60. Escribano-Romero E, Jimenez de Oya N, Domingo E, Saiz JC. Extinction of West Nile virus by favipiravir through lethal mutagenesis. Antimicrob Agents Chemother 2017;61:e01400-e01417. https://doi.org/10.1128/AAC.01400-17
  61. Shannon A, Selisko B, Le NTT, Huchting J, Touret F, Piorkowski G, Fattorini V, Ferron F, Decroly E, Meier C, et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun 2020;11:4682.
  62. Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A 2020;117:26955-26965. https://doi.org/10.1073/pnas.2014441117
  63. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020;6:1192-1198. https://doi.org/10.1016/j.eng.2020.03.007
  64. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020. doi: 10.1101/2020.03.17.20037432.
  65. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020;64:e01897-e20.
  66. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A 2017;114:206-214. https://doi.org/10.1073/pnas.1617020114
  67. Pecheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol 2016;90:3086-3092. https://doi.org/10.1128/JVI.02077-15
  68. Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, Hou W, Cheng L, Xiao H, Yang Z. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 2007;152:1447-1455. https://doi.org/10.1007/s00705-007-0974-5
  69. Wei XF, Gan CY, Cui J, Luo YY, Cai XF, Yuan Y, Shen J, Li ZY, Zhang WL, Long QX, et al. Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay. Antimicrob Agents Chemother 2018;62:e01302-e01318. https://doi.org/10.1128/AAC.01302-18
  70. Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 2020;6:28.
  71. Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect 2020;26:917-921. https://doi.org/10.1016/j.cmi.2020.04.026
  72. Xu P, Huang J, Fan Z, Huang W, Qi M, Lin X, Song W, Yi L. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect 2020;22:200-205. https://doi.org/10.1016/j.micinf.2020.05.012
  73. Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, Dehghan N, Navaei M, Ranjbar M. Effect of Arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis 2020;20:954.
  74. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;55:105938.
  75. Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, Bukhari A, Alfaleh MA, Memish ZA. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review. Travel Med Infect Dis 2020;35:101735.
  76. Khan M, Santhosh SR, Tiwari M, Lakshmana Rao PV, Parida M. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells. J Med Virol 2010;82:817-824.  https://doi.org/10.1002/jmv.21663
  77. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.
  78. RECOVERY Collaborative GroupHorby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020;383:2030-2040. https://doi.org/10.1056/NEJMoa2022926
  79. Gorabi AM, Kiaie N, Bianconi V, Jamialahmadi T, Al-Rasadi K, Johnston TP, Pirro M, Sahebkar A. Antiviral effects of statins. Prog Lipid Res 2020;79:101054.
  80. Takahashi T, Suzuki T. Function of membrane rafts in viral lifecycles and host cellular response. Biochem Res Int 2011;2011:245090.
  81. Fecchi K, Anticoli S, Peruzzu D, Iessi E, Gagliardi MC, Matarrese P, Ruggieri A. Coronavirus interplay with lipid rafts and autophagy unveils promising therapeutic targets. Front Microbiol 2020;11:1821.
  82. Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev 2017;13:209-216. https://doi.org/10.2174/1573403X13666170426104611
  83. Mansur A, Steinau M, Popov AF, Ghadimi M, Beissbarth T, Bauer M, Hinz J. Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study. BMC Med 2015;13:128.
  84. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 2020;32:176-187.e4. https://doi.org/10.1016/j.cmet.2020.06.015
  85. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tre G, Belmans L, Dobson R, Wynendaele E, Van De Wiele C, Vandaele F, et al. The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc 2020;21:909-914.e2. https://doi.org/10.1016/j.jamda.2020.06.018
  86. Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, Longhurst CA, Criqui MH, Messer K. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol 2020;136:149-155. https://doi.org/10.1016/j.amjcard.2020.09.012
  87. Moeller R, Zapatero-Belinchon FJ, Lasswitz L, Kirui J, Brogden G, Gunesch AP, Pietschmann T, Wichmann D, Kluge S, Gerold G. Effect of statins on SARS-CoV-2 infection. medRxiv 2021. doi: 10.1101/2020.07.13.20152272.
  88. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
  89. Hoffmann M, Schroeder S, Kleine-Weber H, Muller MA, Drosten C, Pohlmann S. nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 2020;64:e00754-e20.
  90. Lee ST, Cho H. The use of nafamostat mesilate as an anticoagulant during continuous renal replacement therapy for children with a high risk of bleeding. J Korean Soc Pediatr Nephrol 2014;18:98-105.  https://doi.org/10.3339/jkspn.2014.18.2.98
  91. Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, Kim YL, Kim CD. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore) 2015;94:e2392.
  92. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K, Panis M, Sachs D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020;181:1036-1045.e9. https://doi.org/10.1016/j.cell.2020.04.026
  93. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Pere H, Charbit B, Bondet V, Chenevier-Gobeaux C, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369:718-724. https://doi.org/10.1126/science.abc6027
  94. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020;370:eabd4570.
  95. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Beziat V, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020;370:eabd4585.
  96. Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S, Aoued H, Tharp GM, Pellegrini KL, Manfredi C, et al. Type I and Type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J Virol 2020;94:e00985-e20.
  97. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 2020;27:883-890.e2. https://doi.org/10.1016/j.chom.2020.04.017
  98. Fu W, Liu Y, Xia L, Li M, Song Z, Hu H, Yang Z, Wang L, Cheng X, Wang M, et al. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19. EClinicalMedicine 2020;25:100478.
  99. Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, Qiu F, Wang X, Zou X, Wan D, et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe 2020;28:455-464.e2. https://doi.org/10.1016/j.chom.2020.07.005
  100. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 2020;64:e01061-e20.
  101. Pereda R, Gonzalez D, Rivero HB, Rivero JC, Perez A, Lopez LDR, Mezquia N, Venegas R, Betancourt JR, Dominguez RE. Therapeutic effectiveness of interferon-α2b against COVID-19: the cuban experience. J Interferon Cytokine Res 2020;40:438-442. https://doi.org/10.1089/jir.2020.0124
  102. Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, Fazeli MR, Ghazaeian M, Yekaninejad MS. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol 2020;88:106903.
  103. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2021;9:196-206. https://doi.org/10.1016/S2213-2600(20)30511-7
  104. Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev 2020;33:e00072-e20.
  105. Erkurt MA, Sarici A, Berber I, Kuku I, Kaya E, Ozgul M. Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern Anatolia. Transfus Apher Sci 2020;59:102867.
  106. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324:460-470. https://doi.org/10.1001/jama.2020.10044
  107. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vazquez C, Savoy N, Giunta DH, Perez LG, Sanchez MDL, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 2020. doi: 10.1056/NEJMoa2031304.
  108. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020;11:2251.
  109. Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, Rong B, Li C, Wang S, Chen K, et al. Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection. Cell Reports 2020;32:107918.
  110. Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 2020;368:1274-1278. https://doi.org/10.1126/science.abc2241
  111. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA, Claireaux M, Kerster G, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020;369:643-650. https://doi.org/10.1126/science.abc5902
  112. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med 2021;384:229-237. https://doi.org/10.1056/NEJMoa2029849
  113. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med 2021;384:238-251. https://doi.org/10.1056/NEJMoa2035002
  114. Celltrion. Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms [Internet]. Available at https://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=409 [accessed on 29 December 2020]. 
  115. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26:1636-1643. https://doi.org/10.1038/s41591-020-1051-9
  116. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2:e474-e484. https://doi.org/10.1016/S2665-9913(20)30173-9
  117. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, Sinclaire BA, Bednarz U, Marafelias M, Hansen E, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol 2020;2:e603-e612. https://doi.org/10.1016/S2665-9913(20)30277-0
  118. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020;117:10970-10975. https://doi.org/10.1073/pnas.2005615117
  119. Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, Toko L, Mezher C, Kadiane-Oussou NJ, Bossert M, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020;50:397-400. https://doi.org/10.1016/j.medmal.2020.05.001
  120. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, et al. COVIDOSE: a phase II clinical trial of low-dose tocilizumab in the treatment of noncritical COVID-19 pneumonia. Clin Pharmacol Ther 2020. doi: 10.1002/cpt.2117.
  121. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med 2021;384:20-30. https://doi.org/10.1056/NEJMoa2030340
  122. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med 2020;383:2333-2344. https://doi.org/10.1056/NEJMoa2028836
  123. Tsai A, Diawara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep 2020;10:19131.
  124. Sanofi. Sanofi provides update on Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. [Internet]. Available at https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-01-07-00-00 [accessed on 28 September 2020]. 
  125. Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, Frigeni M, Damiani M, Mico C, Fagiuoli S, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv 2020. doi: 10.1101/2020.04.01.20048561.
  126. Harrison C. Focus shifts to antibody cocktails for COVID-19 cytokine storm. Nat Biotechnol 2020;38:905-908. https://doi.org/10.1038/s41587-020-0634-9
  127. De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, Boffini N, Tentori S, Mette F, Farina N, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol 2020;2:e465-e473. https://doi.org/10.1016/S2665-9913(20)30170-3
  128. Kiniksa. Kiniksa announces data from U.S. investigator-initiated study of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation [Internet]. Available at https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-data-us-investigator-initiated-study [accessed on 23 December 2020]. 
  129. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020;2:e325-e331. https://doi.org/10.1016/S2665-9913(20)30127-2
  130. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache JM, Bezie Y, Laplanche S, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020;2:e393-e400. https://doi.org/10.1016/S2665-9913(20)30164-8
  131. Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H, Al Aghbari J, Al Busaidi I, Al Kindi M, Baawain S, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. Int J Infect Dis 2021;103:288-296. https://doi.org/10.1016/j.ijid.2020.11.149
  132. La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia 2020;34:1805-1815. https://doi.org/10.1038/s41375-020-0891-0
  133. Capochiani E, Frediani B, Iervasi G, Paolicchi A, Sani S, Roncucci P, Cuccaro A, Franchi F, Simonetti F, Carrara D, et al. Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection from RESPIRE protocol. Front Med (Lausanne) 2020;7:466.
  134. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020;146:137-146.e3. https://doi.org/10.1016/j.jaci.2020.05.019
  135. Innes AJ, Cook LB, Marks S, Bataillard E, Crossette-Thambiah C, Sivasubramaniam G, Apperley J, Milojkovic D. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. Br J Haematol 2020;190:e198-e200. https://doi.org/10.1111/bjh.16979
  136. Novartis. Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 2020 [Internet]. Available at https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19 [accessed on 23 December 2020]. 
  137. D'Alessio A, Del Poggio P, Bracchi F, Cesana G, Sertori N, Di Mauro D, Fargnoli A, Motta M, Giussani C, Moro P, et al. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. Leukemia 2021;35:635-638. https://doi.org/10.1038/s41375-020-01087-z
  138. Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, Aquilini D, Landini G, Cimolato B, Pietro MAD, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect 2020;81:647-679. https://doi.org/10.1016/j.jinf.2020.06.052
  139. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2020. doi: 10.1056/NEJMoa2031994.
  140. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 2020;53:368-370. https://doi.org/10.1016/j.jmii.2020.03.005
  141. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-475. https://doi.org/10.1016/S0140-6736(20)30317-2
  142. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med 2020. doi: 10.1056/NEJMoa2021436.
  143. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 2020;324:1307-1316. https://doi.org/10.1001/jama.2020.17021
  144. Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G, Badie J, Francois B, Aubron C, Ricard JD, Ehrmann S, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA 2020;324:1298-1306. https://doi.org/10.1001/jama.2020.16761
  145. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020;324:1317-1329. https://doi.org/10.1001/jama.2020.17022
  146. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324:1330-1341. https://doi.org/10.1001/jama.2020.17023
  147. World Health Organization. Corticosteroids for COVID-19: living guidance [Internet]. Available at https://apps.who.int/iris/handle/10665/334125 [accessed on 23 September 2020].